CRISPR Therapeutics AG logo

CRSP

CRISPR Therapeutics AG

$71.47

Earnings Summary

Revenue
$0.18Mn
Net Profits
$-179.22Mn
Net Profit Margins
-100683.71%
PE Ratio
20.24

Highlights

Revenue:

CRISPR Therapeutics AG’s revenue fell -66.98% since last year same period to $0.18Mn in the Q1 2022. On a quarterly growth basis, CRISPR Therapeutics AG has generated -98.62% fall in its revenue since last 3-months.

Net Profits:

CRISPR Therapeutics AG’s net profit fell -58.37% since last year same period to $-179.22Mn in the Q1 2022. On a quarterly growth basis, CRISPR Therapeutics AG has generated -26.88% fall in its net profits since last 3-months.

Net Profit Margins:

CRISPR Therapeutics AG’s net profit margin fell -379.56% since last year same period to -100683.71% in the Q1 2022. On a quarterly growth basis, CRISPR Therapeutics AG has generated -9094.6% fall in its net profit margins since last 3-months.

PE Ratio:

CRISPR Therapeutics AG’s price-to-earnings ratio after this Q1 2022 earnings stands at 20.24.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the CRISPR Therapeutics AG post its latest quarter earnings

EPS Estimate Current Quarter
-1.94
EPS Estimate Current Year
-1.94

Highlights

EPS Estimate Current Quarter:

CRISPR Therapeutics AG’s earning per share (EPS) estimates for the current quarter stand at -1.94 - a -9.6% fall from last quarter’s estimates.

EPS Estimate Current Year:

CRISPR Therapeutics AG’s earning per share (EPS) estimates for the current year stand at -1.94.

Key Ratios

Key ratios of the CRISPR Therapeutics AG post its Q1 2022 earnings

Earning Per Share (EPS)
-2.32
Return on Assets (ROA)
-0.15
Return on Equity (ROE)
-0.27
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

CRISPR Therapeutics AG’s earning per share (EPS) fell -53.64% since last year same period to -2.32 in the Q1 2022. This indicates that the CRISPR Therapeutics AG has generated -53.64% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CRISPR Therapeutics AG’s return on assets (ROA) stands at -0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CRISPR Therapeutics AG’s return on equity (ROE) stands at -0.27.

Dividend Per Share (DPS):

CRISPR Therapeutics AG declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-1.94
-2.32
-19.59%

Company Information

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Organisation
CRISPR Therapeutics AG
Headquarters
Zug, Zug, Switzerland
Employees
410
Industry
Health Technology
CEO
Samarth Kulkarni